Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone

Journal of the American Society of Nephrology

Volumn 12, Issue 10, 2001, Pages 2051-2059

  Taal, M W ^a   Nenov, V D ^a   Wong, W ^a   Satyal, S R ^a   Sakharova, O ^a   Jeong Hoon Choi, ^a   Troy, J L ^a   Brenner, B M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; OMAPATRILAT; VASOPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; HEMODYNAMICS; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE;

EID: 0034838230     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
2. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
3. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
4. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial: Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN): Ramipril efficacy in nephropathy
5. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
6. Emerging treatments for hypertension: Potential role for vasopeptidase inhibition
7. Vasopeptidase inhibition: A new concept in blood pressure management
8. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats
9. Effects of omapatrilat in low, normal, and high renin experimental hypertension
10. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril
11. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
12. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat
13. Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure
14. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats
15. Eine einfache colorimetrische methode zur inulinbestimmung für nieren-clearanceuntersuchungen bei stoffwechselgesundun und diabetikern
16. Fluometric method for the determination of nanogram quantities of inulin
17. The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man
18. Effects of some vasodilator drugs on transcapillary fluid exchange in renal cortex
19. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation
20. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney
21. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass
22. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass
23. Mechanisms underlying renoprotection during renin-angiotensin system blockade
24. Reversing glomerular hypertension stabilizes established glomerular injury
25. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation
26. Effects of natriuretic peptide receptor inhibition on remnant kidney function in rats
27. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells
28. C-type natriuretic peptide inhibits intimal thickening after vascular injury
29. Vascular actions of brain natriuretic peptide: Modulation by atherosclerosis and neutral endopeptidase inhibition
30. Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep
31. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation
32. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects
33. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: Chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors
34. The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity
35. Role of angiotensin II and bradykinin in experimental diabetic nephropathy: Functional and structural studies
36. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition
37. Angiotensin converting enzyme inhibitor modulates glomemlar function and structure by distinct mechanisms
38. The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin
39. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction
40. Bradykinin metabolism in the postinfarcted rat heart: Role of ACE and neutral endopeptidase 24.11
41. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo
42. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis